Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC
Otolaryngology–Head and Neck Surgery · 2026-01 · 174 (1) · 163-172
DOI: 10.1002/ohn.70051 ↗At a glance
Journal article in Otolaryngology–Head and Neck Surgery, published online on 2025-10-17. Written by Gabriel Raab and 15 co-authors. Institution: Department of Medicine, New York Presbyterian-Weill Cornell Medical College, 525 East 68th Street, New York, USA. Major MEDLINE topics: Cetuximab, Neoadjuvant Therapy, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms. Cited 4 times so far (Crossref); 34 references.
Abstract (original language)
Objective
Taxane, platinum, and cetuximab (TPC) is effective as neoadjuvant therapy for advanced head and neck squamous cell carcinoma (HNSCC) and induces pathologic responses that influences clinical outcomes. Study Design Retrospective cohort study conducted from 1990 to 2023.
Setting
Memorial Sloan Kettering Cancer Center.
Methods
Patients with HNSCC who received TPC/TPF before definitive therapy were retrospectively reviewed. Patients were assessed for radiographic and pathologic response, disease‐free survival (DFS), and overall survival (OS). Radiographic response was defined as any tumor shrinkage assessed by a radiologist. Pathologic response on the primary (tumor) and lymph nodes was categorized as complete (pCR), near complete (pNCR), partial (pPR), and no response (pNR), corresponding to treatment effects of 100%, 90%‐99%, 11%‐89%, and
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medicine, New York Presbyterian-Weill Cornell Medical College, 525 East 68th Street, New York, USA.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, USA.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, USA.
- Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, USA.
Cite
APA
Raab, G., Xu, B., Alabkaa, A., Katabi, N., Dogan, S., Dunn, L., Patel, S., Sherman, E. J., Pfister, D., Tam, K., Caxeiro, G., Ghossein, R., Cracchiolo, J., Ho, A. L., Ganly, I., & Wong, W. (2026). Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC. Otolaryngology–Head and Neck Surgery, 174(1), 163-172. https://doi.org/10.1002/ohn.70051
Vancouver
Raab G, Xu B, Alabkaa A, Katabi N, Dogan S, Dunn L, et al. Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC. Otolaryngology–Head and Neck Surgery. 2026;174(1):163-172. doi:10.1002/ohn.70051
BibTeX
@article{Raab2026,
author = {Raab, Gabriel and Xu, Bin and Alabkaa, Anas and Katabi, Nora and Dogan, Snjezana and Dunn, Lara and Patel, Snehal and Sherman, Eric J and Pfister, David and Tam, Kenric and Caxeiro, Giovanna and Ghossein, Ronald and Cracchiolo, Jennifer and Ho, Alan L and Ganly, Ian and Wong, Winston},
title = {Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2026},
volume = {174},
number = {1},
pages = {163--172},
doi = {10.1002/ohn.70051}
}
EUVIMED